<qa>  What is the goal of this study?It was found in the treatment of HCC using p53 gene therapy that the concurrent diabetes was controlled as well. The objectives of this study are to investigate both anti-diabetic and anti-tumor role of p53 gene therapy. This is an open-labeled, randomized, active-controlled phase 2 study. p53 will be injected via the artery, which supplies blood for the tumor nodules. The study endpoints for anti-diabetic role are fasting plasma glucose FPG, postprandial glucose PPG and glycosylated hemoglobin A1C at 30 days after the start of treatment; and for antitumor effect are progression-free survival and overall survival. 